Possible involvement of nitric oxide in antidepressant-like effect of silymarin in male mice

Pharmaceutical Biology

Volumn 53, Issue 5, 2015, Pages 739-745

  Khoshnoodi, Mina ^a,b   Fakhraei, Nahid ^a,b   Dehpour, Ahmad Reza ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Depression; Forced swimming test; Open field test; Tail suspension test

Indexed keywords

AMINOGUANIDINE; FLUOXETINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SILYMARIN; ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FORCED SWIM TEST; IMMOBILITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; TAIL SUSPENSION TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DRUG EFFECTS; FEMALE; IMMOBILIZATION; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; TREATMENT OUTCOME;

ASTERACEAE; MUS; SILYBUM MARIANUM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMOBILIZATION; MALE; MICE; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; SILYMARIN; TREATMENT OUTCOME;

EID: 84924420096     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.942787     Document Type: Article

References (68)

1. Bannwart CF, Nakaira-Takahagi E, Golim MA, et al. (2010). Down regulation of nuclear factor-kappa B (NF-kappaB) pathway by silibinin in human monocytes challenged with Paracoccidioides brasiliensis. Life Sci 86:880-6.
2. Bansal N, Gill R, Gupta GD. (2013). Silymarin: A flavolignan with antidepressant activity. J Pharm Innov 5:93-8.
3. Belmaker RH, Agam G. (2008). Major depressive disorder. N Engl J Med 358:55-68.
4. Berk M, Kapczinski F, Andreazza AC, et al. (2011). Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 353:804-17.
5. Capuron L, Miller AH. (2011). Immune system to brain signaling neuropsychopharmacological implications. Pharmacol Ther 130: 226-38.
6. Chrapko WE, Jurasz P, Radomski MW, et al. (2004). Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 56:129-34.
7. Demirci B, Demir O, Dost T, Birincioglu M. (2014). Treated effect of silymarin on vascular function of aged rats: Dependant on nitric oxide pathway. Pharm Biol 52:453-7.
8. Desplaces A, Choppin J, Vogel G, Trost W. (1975). The effect of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 25:89-96.
9. Dhingra D, Sharma A. (2005). Evaluation of antidepressant-like activity of glycyrrhizin in mice. Indian J Pharmacol 37:390-4.
10. Dhir A, Kulkarni SK. (2007a). Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 31:921-5.
11. Dhir A, Kulkarni SK. (2007b). Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 30:177-85.
12. Finney DJ. (1971). Probit Analysis. Cambridge: Cambridge University Press.
13. Fontella FU, Siqueira IR, Vasconcellos APS, et al. (2005). Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem Res 30:105-11.
14. Galhardi F, Mesquita K, Monserrat JM, Barros DM. (2009). Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol 47:2655-60.
15. Ghasemi M, Raza M, Dehpour AR. (2010). NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol 244:585-94.
16. Gibson SA, Korade Z, Shelton RC. (2012). Oxidative stress and glutathione response in tissue cultures from persons with major depression. J Psychiatr Res 46:1326-32.
17. Goodnick PJ, Goldstein BJ. (1998). Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol 12(3 Suppl B):S5-20.
18. Harkin A, Connor TJ, Burns MP, Kelly JP. (2004). Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 14:274-81.
19. Heiberg IL, Wegener G, Rosenberg R. (2002). Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134:479-84.
20. Hua Y, Huang X-Y, Zhou L, et al. (2008). DETA/NONOate, a nitric oxide donor, produces antidepressant effects by promoting hippo-campal neurogenesis. Psychopharmacology 200:231-42.
21. Jesmin J, Rashid MS, Jamil H, et al. (2010). Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genom 3:45.
22. Karimi G, Saradeghi Keisari M. (2007). Evaluation of antidepressant effect of ethanolic and aqueous extracts of Silybum marianum L. seed in mice. J Med Plants 6:38-43.
23. Kaster MP, Ferreira PK, Santos ARS, Rodrigues ALS. (2005). Effects of potassium channel inhibitors in the forced swimming test: Possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res 165:204-9.
24. Kren V, Walterova D. (2005). Silybin and silymarin-New effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:29-41.
25. Lecomte J. (1975). Les propriétés pharmacologiques de la silybine et de la silymarine. Rev Med Liege XXX:110-14.
26. Lu D, Mahmood A, Zhang R, Copp M. (2003). Upregulation of neurogenesis and reduction in functional deficits following administration of DEtA/NONOate, a nitric oxide donor, after traumatic brain injury in rats. J Neurosurg 99:351-61.
27. Lu P, Mamiya T, Lu L, et al. (2009a). Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res 207:387-93.
28. Lu P, Mamiya T, Lu LL, et al. (2009b). Silibinin prevents amyloid peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 157:1270-7.
29. Lucca G, Comim CM, Valvassori SS, et al. (2009). Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 54:358-62.
30. Luo CX, Zhu XJ, Zhou QG, et al. (2007). Reduced neuronal nitric oxide synthase is involved in ischemia-induced hippocampal neurogenesis by up-regulating inducible nitric oxide synthase expression. J Neurochem 103:1872-82.
31. Mantovani M, Pértile R, Calixto JB, et al. (2003). Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: Evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett 343:1-4.
32. Mazzio E, Harris N, Soliman K. (1998). Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 64:603-6.
33. Miller AH, Maletic V, Raison CL. (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 659:732-41.
34. Muller N, Schwarz MJ, Dehning S, et al. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 117:680-4.
35. Murata N, Murakami K, Ozawa Y, et al. (2010). Silymarin attenuated the amyloid b plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model. Biosci Biotechnol Biochem 74: 2299-306.
36. Muzes G, Deak G, Lang I, et al. (1991). Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase enzyme. Acta Physiol Hung 78:3-9.
37. Nencini C, Giorgi G, Micheli L. (2007). Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14:129-35.
38. Nery FG, Monkul ES, Hatch JP, et al. (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 232:87-94.
39. Ng F, Berk M, Dean O, Bush AI. (2008). Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851-76.
40. Osuchowski M, Johnson V, He Q, Sharma R. (2004). Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture, in BALB/c mice. Pharm Biol 42:384-9.
41. Owolabi RA, Akanmu MA, Adeyemi OI. (2014). Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. Neurosci Lett 566: 172-6.
42. Peng YL, Liu YN, Liu L, et al. (2012). Inducible nitric oxide synthase is involved in the modulation of depressive behaviors induced by unpredictable chronic mild stress. J Neuroinflammation 9:75. doi:10.1186/1742-2094-9-75.
43. Porsolt RD, Bertin A, Jalfre M. (1977). Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-36.
44. Rana P, Agarwal S, Agarwal R. (2006). Prostate cancer chemoprevention by silybinin: Bench to bedside. Mol Carcinog 45:436-42.
45. Rauen U, de Groot H. (1998). Cold-induced release of reactive oxygen species as a decisive mediator of hypothermia injury to cultured liver cells. Free Radic Biol Med 24:1316-23.
46. Refaey El H, Amri HS, SSC-Psych. (2011). Effects of antidepressants on behavioral assessment in adolescent rats. Bahrain Med Bull 33:83-95.
47. Reid C, Edwards J, Wang M, et al. (1999). Prevention by a silymarin/phospholipid compound of ethanol-induced social learning deficits in rats. Planta Med 655:421-4.
48. Rodrigues ALS, Silva GL, Matteussi AS, et al. (2002). Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 70: 1347-58.
49. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, et al. (2011). Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res 2242:336-43.
50. Salamone F, Galvano F, Cappello F, et al. (2012). Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 159:477-86.
51. Scapagnini G, Davinelli S, Drago F, et al. (2012). Antioxidants as antidepressants: Fact or fiction. CNS Drugs 6:477-90.
52. Shanmugam K, Holmquist L, Steele M, et al. (2008). Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macro-phages. Mol Nutr Food Res 52:427-38.
53. Sharma U, Lahkar M, Lahon J. (2012). Evaluation of antidepressant like activity of silymarin in albino mice. IJAPR 11:1246-9.
54. Shin JH, Lee CW, Oh SJ, et al. (2013). Protective effect of silymarin against ethanol-induced gastritis in rats: Role of sulfhydryls, nitric oxide and gastric sensory afferents. Food Chem Toxicol 55:353-7.
55. Singhal NK, Srivastava G, Patel DK, et al. (2011). Melatonin or silymarin reduces maneb-and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 50:97-109.
56. Solati J, Yaghmaei P, Mohammdadi K. (2012). Role of the 5-HT1A serotonergic system in anxiolytic-like effects of silymarin. Neurophysiology 44:49-55.
57. Steru L, Chermat R, Thierry B, Simon P. (1985). The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berlin) 853:367-70.
58. Thomas T. (2000). Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21:343-8.
59. Trouillas P, Marsal P, Svobodova A, et al. (2008). Mechanism of the antioxidant action of silybin and 2, 3-dehydrosilybin flavono-lignans: A joint experimental and theoretical study. J Phys Chem A 112:1054-63.
60. Vogel G, Trost W, Braatz R. (1975). Untersuchungen zu pharmakody-namik, angriffspunkt und wirkungsmechanismsus von silymarin, dem antihepatotoxischen prinzip aus Silybum marianum (L.) Gaertn. Arzneimittelforschung 25:82-9.
61. Volke V, Wegener G, Bourin M, Vasar E. (2003). Antidepressant-and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 140: 141-7.
62. Wagner VH, Diesel P, Seitz M. (1974). Chemistry and analysis of silymarin from Silybum marianum (L.) Gaertn. Arzneimittelforschung 24:466-71.
63. Wang D, An SC, Zhang X. (2008). Prevention of chronic stress-induced depression like behavior by inducible nitric oxide inhibitor. Neurosci Lett 433:59-64.
64. Wang MJ, Lin WW, Chen HL, et al. (2002). Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 1611: 2103-12.
65. Wellington K, Jarvis B. (2001). Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 15:465-89.
66. Yaghmaei P, Oryanb S, Mohammadia K, Solati J. (2012). Role of serotonergic system on modulation of depressogenic-like effects of silymarin. Iran J Pharm Res 111:331-7.
67. Zhang R, Zhang L, Zhang Z. (2001). A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol 50:602-11.
68. Zhu XJ, Hua Y, Jiang J, et al. (2006). Neuronal nitric oxide synthase-derived nitric oxide inhibits neurogenesis in the adult dentate gyrus by down-regulating cyclic AMP response element binding protein phosphorylation. Neuroscience 141:827-35.